Statement: There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial
Primary_evidence: Adverse Events 1:   Total: 8/86 (9.30%)   Hypersensitivity reaction to Cisplatin 1/86 (1.16%)   Infection with normal ANC 4/86 (4.65%)   Neutrophil Count 1/86 (1.16%)   Hyperglycemia 1/86 (1.16%)   Hypertension 1/86 (1.16%)
Secondary_evidence: Adverse Events 1:   Total: 20/88 (22.73%)   Cardiac Failure * 2/88 (2.27%)   Intracardiac thrombus * 1/88 (1.14%)   Abdominal pain * 1/88 (1.14%)   Diarrhoea * 2/88 (2.27%)   Enteritis * 1/88 (1.14%)   Intestinal perforation * 1/88 (1.14%)   Chest pain * 1/88 (1.14%)   Death * 1/88 (1.14%)   Erysipelas * 1/88 (1.14%)   Pneumonia * 1/88 (1.14%)   Abdominal wound dehiscence * 1/88 (1.14%)